ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

FDA: Oncology Division Director Delap Promoted In Agency

May 29, 1998

Venter Steps Down As Celera President; Moffitt, Puerto Rico Center Win NCI P20 Grant.

January 25, 2002

Funding opportunities listed.

May 7, 2004

Obituaries: Sylvan Green, Donald Gleason

January 23, 2009

Investigational Drug Radium-223 Chloride Improved Overall Survival By 44 Percent

September 30, 2011

House Committee Gives NCI Only $6.5 Million Over President’s request

July 28, 1989